FLEX NEOADJUVANT PUBLICATIONS & ABSTRACTS
Clinical evidence from FLEX
Evidence / Neoadjuvant / FLEX
MammaPrint and BluePrint Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX
Title: MammaPrint® and BluePrint® Predict Pathological Response to Neoadjuvant Chemotherapy in Patients With HR+HER2- Early-Stage Breast Cancer Enrolled in FLEX Background: For patients with hormone receptor-positive (HR+), HER2-negative early-stage breast cancer (EBC), pathological Complete Response (pCR) rates to neoadjuvant chemotherapy (NCT) are low. However, NBRST and I-SPY2 trials report Read More
Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine- Biology is Still King
Title: Neoadjuvant Chemotherapy for T3 tumors in the Era of Precision Medicine- Biology is Still King Authors: Rakhshanda Rahman, Christin Collins*, Laura Lee, Alfredo Santillan, Mehran Habibi, Peter Blumencranz, Charlie Cox, James Pellicane, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O'Shaughnessy *Presenting Author Read More
Improved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreEBCC 2024: The New Era of Genomic Testing in Early Stage Breast Cancer
EBCC 2024, Oral Presentation Presenter: Dr. Caroline Drukker
Read MoreMammaPrint + BluePrint predict anthracycline chemosensitivity, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 36 Authors: Audeh et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read More
